Table 2.

Clinical characteristics, microbiological findings, treatment, and outcome of the of CoNS meningitis in our series

Characteristics	Patient 1	Patient 2	Patient 3	Patient 4	Patient 5	Patient 6	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	Patient 12
Age (years)/sex	32/male	40/female	28/male	21/male	38/male	39/female	24/male	43/male	56/male	47/male	39/male	54/male
Nationality	Nepalese	Filipino	Sri Lankan	Nepalese	Bangladeshi	Indonesian	Nepalese	Nepalese	Iraqi	Jordanian	Nepalese	Cyprus
Infection onset after procedures (days)		10	16	13	18	22	15	10	11	7	13	14
Underlying neurosurgical condition
Head injury	No	Yes	No	Yes	No	No	No	No	No	No	No	No
Intracerebral hg	No	No	No	No	Yes	Yes	No	Yes	No	Yes	Yes	Yes
Brain tumor	Yes	No	No	No	No	No	No	No	No	No	No	No
Hydrocephalus	Yes	No	Yes	No	No	No	Yes	No	Yes	No	No	No
Associated  bacteremia	No	No	Yes	No	No	No	No	No	No	No	Yes	No
Infection setting	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial	Nosocomial
Neurosurgical device	VP shunt	EVD	VP shunt	EVD	EVD	EVD	VP shunt	EVD	VP shunt	EVD	EVD	EVD
Comorbidities
Hypertension	No	Yes	No	No	Yes	Yes	No	Yes	No	Yes	Yes	Yes
AVM	No	No	No	No	No	No	No	No	No	No	No	No
Staphylococcus species	S. epidermidis	S. epidermidis	S. haemolyticus	S. epidermidis	S. epidermidis	S. capitis	S. epidermidis	S. epidermidis	S. epidermidis	S. epidermidis	S. haemolyticus	S. capitis
Antimicrobials susceptibility
Amoxil/calv	R	R	R	S	R	R	S	ND	R	R	R	R
Vancomycin	S	S	S	S	S	S	S	S	S	S	S	S
Tazocin	R	R	R	S	R	R	S	ND	R	R	R	R
Linezolid	ND	ND	S	S	ND	ND	S	ND	S	S	S	ND
Teicoplanin	ND	S	S	S	ND	S	S	S	S	S	S	ND
Oxacillin	R	R	R	S	R	R	S	S	R	R	R	R
Ceftriaxone	R	R	R	S	R	R	ND	S	R	R	R	R
Empirical therapy	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Meropenem + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin	Ceftriaxone + vancomycin
Duration of therapy (days)	3	6	5	5	4	5	4	3	4	3	3	6
Definitive therapy	Vancomycin	Vancomycin	Linezolid	Cloxacillin	Vancomycin	Vancomycin	Cloxacillin	Cloxacillin	Vancomycin	Linezolid	Vancomycin	Vancomycin
Duration of therapy (days)	14	15	10	12	10	12	20	13	10	14	14	14
EVD removal	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Outcome	Cured	Cured	Cured	Cured	Cured	Cured	Cured	Cured	Cured	Cured	Cured	Cured

R – Resistant; S – Sensitive; ND – Not done; EVD – External ventricular drain; VP – ventriculoperitoneal; S. capitis – Staphylococcus capitis; S. epidermidis – Staphylococcus epidermidis; S. haemolyticus – Staphylococcus haemolyticus; AVM – Arteriovenous malformation